Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

MeSH terms

• Antimetabolites, Antineoplastic / administration & dosage
• Antimetabolites, Antineoplastic / adverse effects
• Antimetabolites, Antineoplastic / therapeutic use
• Azacitidine / administration & dosage
• Azacitidine / adverse effects*
• Azacitidine / analogs & derivatives*
• Azacitidine / analysis
• Azacitidine / therapeutic use
• Decitabine
• Dose-Response Relationship, Drug
• Humans
• Injections, Subcutaneous
• Male
• Middle Aged
• Primary Myelofibrosis / complications
• Primary Myelofibrosis / drug therapy*
• Risk Factors
• Sweet Syndrome / chemically induced
• Sweet Syndrome / complications
• Sweet Syndrome / prevention & control*
• Treatment Outcome